I am an attending physician on the Lymphoma Service in the Department of Medicine. I have had a large clinical practice for more than 30 years, which includes primarily patients with malignant lymphomas, chronic lymphocytic leukemia, and multiple myeloma. I have a longstanding clinical research interest in malignant lymphomas, and have authored more than 150 publications on this topic. I have conducted clinical trials in Hodgkin lymphoma, cutaneous T-cell lymphomas, and HIV-associated lymphomas, as well as studies assessing quality of life and survivorship issues among people with lymphoma.
I chaired a national study of the treatment of patients with early-stage Hodgkin lymphoma for the Cancer and Leukemia Group B (CALGB), and will also be chairing a national trial for the same population of patients for CALGB in collaboration with two other National Cancer Institute-sponsored cancer clinical trials groups: the Southwest Oncology Group and the Eastern Cooperative Oncology Group. In other research projects, I am documenting and attempting to improve the outcome of long-term Hodgkin lymphoma survivors. I am also directing multi-institutional clinical trials evaluating new treatments for elderly patients with aggressive non-Hodgkin lymphoma whose disease relapsed after initial chemotherapy, and in patients with advanced cutaneous T-cell lymphomas.
I have served as a reviewer for many publications in the field of the malignant lymphomas and for a number of grant applications for the National Institutes of Health.
- Clinical Expertise: Hodgkin and non-Hodgkin Lymphomas; Multiple Myeloma; Chronic Lymphocytic Leukemia
- Languages Spoken: English
- Education: MD, Medical College of Wisconsin (Marquette)
- Residencies: Montefiore Medical Center
- Fellowships: Beth Israel Hospital/Peter Bent Brigham Hospital; Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Hematology; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Co-Investigated by David J. Straus
- A Phase I/II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma
- A Phase II Study of Dose-Adjusted EPOCH Chemotherapy with or without Rituximab in Patients with Untreated Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, or Plasmablastic Lymphoma
- A Pilot Study of AVD plus Brentuximab Vedotin to Treat Stage II-IV HIV-Associated Hodgkin Lymphoma
- Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
- Prospective Ascertainment for Late Effects Among Cancer Survivors
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more